STEMETIL prochlorperazine mesilate 12.5 mg/mL Injection ampoule (export)

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

prochlorperazine mesilate, Quantity: 12.5 mg/mL

Disponibbli minn:

Sanofi-Aventis Australia Pty Ltd

INN (Isem Internazzjonali):

prochlorperazine mesilate

Għamla farmaċewtika:

Injection

Kompożizzjoni:

Excipient Ingredients: sodium metabisulfite; monoethanolamine; sodium sulfite; water for injections; sodium chloride

Rotta amministrattiva:

Intramuscular

Unitajiet fil-pakkett:

10 x 1 mL

Tip ta 'preskrizzjoni:

(S1) This Schedule is intentionally blank

Indikazzjonijiet terapewtiċi:

STEMETIL is used in vertigo due to Meniere?s syndrome, labyrinthitis and other causes, and for nausea and vomiting from whatever cause. It may also be used for migraine, schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short term management of anxiety.

Sommarju tal-prodott:

Visual Identification: Clear solution, almost colourless or not more than very pale yellow.; Container Type: Ampoule; Container Life Time: 5 Years; Container Temperature: Store below 25 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2007-07-16